🖼

Figure 6 — Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyel

active
paper figure Created: 2026-04-21T18:29:40 By: paper_figures_tool Quality: 50% 🔗 External ID: paper-fig-paper-40988129-6
Figure 6 — Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyel
Figure 6Figure 6
Proposed diagnostic flow chart for differentiating MOGAD, NMOSD and MS based on CSF biomarkers. Flow diagram illustrating a proposed decision pathway for the differential diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) in patients presenting with acute clinical worsening and MRI evidence of new lesion formation. Initial separation is based on CSF levels of granulocyte activation markers (GAM) and complement factors C5/C5a. If elevated, differentiation between MOGAD and NMOSD is guided by astrocytic damage markers GFAP and S100B. Absence of biomarker increases suggests a diagnosis of MS.
PubMed: paper-40988129
Metadata
pmidpaper-40988129
captionProposed diagnostic flow chart for differentiating MOGAD, NMOSD and MS based on CSF biomarkers. Flow diagram illustrating a proposed decision pathway for the differential diagnosis of myelin oligoden
image_urlhttps://www.ebi.ac.uk/europepmc/articles/PMC13058455/bin/awaf345f6.jpg
paper_titleGranulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.
figure_labelFigure 6
figure_number6
_schema_version1
source_strategypmc_api
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
View full evidence profile →
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.